Aurinia Pharmaceuticals, Inc. (AUPH)
15.88
+0.41
(+2.65%)
USD |
NASDAQ |
Dec 11, 16:00
15.90
+0.02
(+0.13%)
After-Hours: 20:00
Aurinia Pharmaceuticals Cash from Investing (Quarterly): -14.04M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 201.61M |
| Oncolytics Biotech, Inc. | -0.0051M |
| Edesa Biotech, Inc. | 0.00 |
| Lexaria Bioscience Corp. | -0.1579M |
| Xenon Pharmaceuticals, Inc. | 38.76M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 44.99M |
| Cash from Financing (Quarterly) | -10.36M |
| Free Cash Flow | 120.39M |
| Free Cash Flow Per Share (Quarterly) | 0.3303 |
| Free Cash Flow to Equity (Quarterly) | 48.54M |
| Free Cash Flow to Firm (Quarterly) | 46.01M |
| Free Cash Flow Yield | 5.37% |